Open access peer-reviewed chapter
Haemophilia severity classification on the basis of FVIII:C/FIX:C levels.
Abstract
Haemophilia was previously regarded as a classical example of Mendelian inheritance, with mutation in only a single gene (F8 or F9) causing the disease phenotype. The disease manifests complete penetrance. Studies, however, revealed the striking genetic and phenotypic heterogeneities of the disease. With further sophistication of clinical and molecular techniques, the disease was also found to have allele heterogeneity, phenotypic plasticity and variation in expressivity. The variations are more pronounced in F9 variants with five distinct phenotypes. All these phenomena advocate a rather complex genotype-phenotype relationship for the disease. A keen insight into the matter may unveil new avenues of therapeutics.
Keywords
- genotype-phenotype correlation
- genotype-phenotype heterogeneity
- haemophilia
1. Phenotypic variation
1.1 Background
A phenotype is defined as an observable characteristic which is expressed by an underlying genotype interacting with the environment [1]. Phenotype, in clinical scenario, hence represents the observable interface of the disease in terms of clinical features (laboratory findings, signs and symptoms) [2]. In contrast to genotype which is a stable entity, phenotype is dynamic and influenced by both the genotype and environment [3, 4]. Hence, in strict terms, the exact disease phenotype may be difficult to ascertain in many cases. This uncertainty usually underlies contemporary processes, directly or indirectly affecting the disease, with their own genetic and/or environmental influences [2]. Precise definition for a specific phenotype, therefore, needs development of a standardised comprehensive checklist of signs, symptoms and laboratory findings [3]. This is considerably convenient in case of monogenic disorders. Phenotypes for multigenic disorders or genetic diseases significantly influenced by environmental interactions are difficult to delineate [5].
1.2 Phenotypic variation in haemophilia
Haemophilia is known to mankind since ancient times with references from Babylonian history [6]. The first vague description of cases appeared in the tenth century [7]. The first modern description of the disease was made in the eighteenth century, and the term haemophilia was first used in 1828 by Johann Lukas Schönlein and his student Friedrich Hopff [6].
The two diseases, haemophilia A (HA) and haemophilia B (HB), were initially regarded as the same and attributed to fragility of vessels [8]. The idea later shifted to abnormalities in platelets in the 1930s. It was in 1937, when Patek and Taylor found the ‘anti-haemophilic globulin’, extracted from plasma, to be the factor responsible. The two diseases were, however, first discriminated in 1944 by Pavlosky of Buenos Aires [8].
In haemophilia, the phenotype is expressed at three distinct levels: the coagulation activity, the factor antigen level and the clinical outcome in terms of bleeding and its complications. Plasma procoagulant level, determined by coagulation activity, is the most important clinical entity determining severity of the disease. Employing this parameter, the Scientific and Standardisation Committee classified haemophilia A and haemophilia B into three major classes, that is, mild, moderate and severe [9]. Each phenotype has a distinct clinical impact (Table 1). Patients with severe phenotype (plasma factor level < 0.01 IU/ml; <1% of normal) commonly present with frequent (two to five bleeding episodes per month) spontaneous bleeding into the joints or deep muscles. Patients with moderate severity of the disease (plasma factor level 0.01–0.05 IU/ml; 1–5% of normal) would bleed following mild trauma; spontaneous bleeding is seen uncommonly. Diagnosis is usually established in the first 5–6 years of life. Bleeding frequency ranges from once a month to once a year. In mild severity of the disease (plasma factor level >0.05 to <0.40 IU/ml; >5 to <40% of normal), bleeding occurs as a result of major trauma, e.g., surgery or accident. Bleeding is infrequent in these patients [10, 11].
| Severity | FVIII:C/FIX:C level (%) | Age at diagnosis | Bleeding and haemarthroses |
|---|---|---|---|
| Severe | ≤1 | ≤2 years | Spontaneous haemorrhages and haemarthroses since early childhood |
| Moderate | 2–5 | <6 years | Haemorrhage are usually secondary to minor trauma or surgery; spontaneous haemarthrosis is unusual |
| Mild | 6–40 | Subject to haemostatic challenge | Haemorrhage secondary to surgery or major trauma; spontaneous bleedings are rare |
Table 1.
FVIII:C, factor VIII coagulation activity; FIX:C, factor IX coagulation activity.
This is, however, noteworthy that patients with a specific severity of the disease do not always behave as anticipated. Studies have reported a significant number of severe haemophilia cases with a milder phenotype [1, 12, 13]. In such cases, bleeding phenotype resembles that of moderate severity. These cases are hence treated like moderate haemophilia; prophylactic treatment is often not needed.
Advertisement
2. Genetic heterogeneity in haemophilia
Haemophilia was previously regarded as a classical example of Mendelian inheritance, with mutation in only one gene (F8 or F9) causing the disease phenotype. The concept, however, has significantly evolved in the last couple of decades, and the two diseases are now recognised to have a heterogeneous spectrum of mutations. More than 2800 mutations are reported in F8, whereas more than 1200 mutations are reported in F9 [14]. These mutations, summarised in Table 2, include all the major types of mutations. Point mutations are the most frequent, followed by small indel mutations. Repeat variants are not yet reported to associate with the disease. In majority of the cases, specific mutations result in the same disease severity, a phenomenon referred to as genotype-phenotype correlation [13, 15].
2.1 Disease penetrance and expressivity
Penetrance refers to the appearance of disease in affected individuals, whereas expressivity is the degree of severity of disease in patients [16]. Haemophilia is an X-linked recessive genetic disorder with complete penetrance in most of the cases, that is, male individuals with pathogenic variants in F8 or F9 are mostly fated to have haemophilia. This stands true particularly in case of F8. Patients from the same family have approximately the same severity status. However, the severity, as described earlier, is not the same in all patients. Cases with the same mutations exhibiting different levels of coagulation factor activity advocate variable expressivity for the specific genotype. This variation is believed to be the outcome factors including genetic alterations or polymorphisms in other genes (especially those related to haemostasis, inflammation and immune response) and environmental factors [17]. It has been established that the same genotype subjected to different environments expresses diverse phenotypes [18]. This interaction between genotype and environment is called gene–environment interaction [19, 20].
Large structural changes in the protein, by default, tend to generate a severe phenotype. Nonsense mutations, particularly those occurring in the early gene segments, have a similar tendency. Almost all the nonsense mutations reported within the initial part of the gene are associated with severe disease phenotype. Frameshift mutations in F8/F9 gene are again usually associated with an adverse phenotype [21].
Approximately 30% of the female individuals with heterozygous mutation have a coagulation factor activity less than 40% [22]. Increased bleeding tendency among the carriers, in comparison to normal females, is well documented [23, 24].
In case of F9 sequence variants, besides classical HB, four other phenotypes are reported. These are described in the following sections.
2.1.1 Haemophilia B Leyden
Haemophilia B Leyden is a specific type of HB in which the patient presents with decreased FIX:C levels in the early childhood, but the levels progressively increase after puberty. The disease is postulated to occur as a result of mutation in the 50 bp region that spans the transcriptional start site [25]. A total of 23 promoter region mutations have been identified until now (Table 3).
| Mutation type | F8 | F9 |
|---|---|---|
| Missense/nonsense | 1674 | 748 |
| Splicing | 193 | 101 |
| Regulatory | 10 | 28 |
| Small deletions | 489 | 161 |
| Small insertions | 160 | 52 |
| Small indels | 38 | 17 |
| Gross deletions | 260 | 75 |
| Gross insertions/duplications | 40 | 7 |
| Complex rearrangements | 20 | 13 |
| Repeat variations | 0 | 0 |
| Total |
Table 2.
Frequency of different types of mutations reported in F8 and F9.
F8, factor VIII gene; F9, factor IX gene.
| HGVS cDNA name | Legacy nucleotide no. | Nature of mutation | Disease severity | Reference |
|---|---|---|---|---|
| c.-55G>A | -26 | Substitution | Moderate | [26] |
| c.-55G>C | -26 | Substitution | Severe | [27] |
| c.-55G>T | -26 | Substitution | Severe | [28] |
| c.-53A>G | -24 | Substitution | Not reported | [21] |
| c.-52C>G | -23 | Substitution | Not reported | [21] |
| c.-52C>T | -23 | Substitution | Not reported | [29] |
| c.-50T>G | -21 | Substitution | Not reported | [30] |
| c.-49T>A | -20 | Substitution | Moderate/mild | [31] |
| c.-49T>C | -20 | Substitution | Mild | [32] |
| c.-48G>C | -19 | Substitution | Moderate/mild | [29] |
| c.-35G>A | -6 | Substitution | Mild | [33] |
| c.-35G>C | -6 | Substitution | Mild | [34] |
| c.-34A>G | -5 | Substitution | Mild | [26] |
| c.-34A>T | -5 | Substitution | Moderate | [35] |
| c.-24T>A | 6 | Substitution | Mild | [34] |
| c.-23T>C | 7 | Substitution | Not reported | [21] |
| c.-22T>C/c | 8 | Substitution | Mild | [36] |
| c.-22delT | 8 | Deletion | Moderate | [21] |
| c.-21C>G | 9 | Substitution | Not reported | [21] |
| c.-18A>G | 12 | Substitution | Moderate | [21] |
| c.-17A>C | 13 | Substitution | Severe | [26] |
| c.-17A>G | 13 | Substitution | Mild | [37] |
| c.-17delA | 13 | Deletion | Mild | [37] |
Table 3.
F9 promoter site mutations associated with HB Leyden (mutation c.-55G>C is an exception).
HGVS, Human Genome Variation Society; no., number.
The mutation at c.-55G>C (or c. -26G>C in legacy nucleotide numbering) found in the promoter region of F9 gene is also called the haemophilia B Brandenburg mutation [38]. Unlike HB Leyden this variant does not exhibit improvement in FIX:C levels with age. The promoter region sequence located at c.-34 to -10 of the F9 gene serves as a binding site for the hepatocyte nuclear factor 4 (HNF4). The liver-enriched HNF4 is a member of the steroid hormone receptor superfamily of transcription factors (also called the nuclear receptor superfamily). Mutation at HNF4 disrupts the binding site to variable extents of severity. The mutation c.-55G>C, however, occurs at a site which is overlapped by the HNF4 binding site and another regulatory region, the androgen-responsive element (ARE) [39].
2.1.2 Thrombophilia
The F9 mutation c.1151G>T is associated with several fold increase in FIX:C activity [40]. The mutant FIX has leucine substituted for arginine at p.Arg384Leu. This alteration increases the affinity for FX to bind at this site. Patients might present with thromboembolic complications. This variant was named ‘factor IX Padua’. Studies have also demonstrated that Arg-338 is part of an exosite (a secondary binding site) that binds factor X and heparin at the same time [41].
People with FIX:C levels more than 129 U/dL are 2–3 times more at risk of developing DVT in comparison to those with lower FIX:C levels. The risk is higher in females [42]. Variations in F9-associated single-nucleotide polymorphisms (SNPs) do not explain this raise in FIX antigen levels [43].
2.1.3 Protection against DVT
The Malmo polymorphism, c.580G>A (p. Ala194Thr), has an allele frequency of 0.32 in the Western population. It has been found that people with the G allele (F9 Malmo) have a 15–43% decreased risk of developing DVT in comparison to those with A allele [44]. This protective role of F9 Malmo has been extensively studied and confirmed [45]. The biochemical mechanisms behind this phenomenon are still obscure.
2.1.4 Warfarin sensitivity
All vitamin K-dependent clotting factors [including FII, FVII, FIX, FX, protein C (PC), protein S (PS) and protein Z (PZ)] possess an 18 amino acid propeptide sequence which serves as a binding site for the γ-glutamyl carboxylase enzyme. This enzyme catalyses modification of certain glutamate residues in the amino terminus of the mentioned clotting factors [46]. It has been determined that mutations at this site reduce the affinity vitamin K-dependent γ-carboxylase for the proteins.
Advertisement
3. Phenotypic plasticity
Phenotypic plasticity is defined as ‘the ability of individual genotypes to produce different phenotypes when exposed to different environmental conditions’ [47]. In the current scenario, this refers to presentation of the same mutation with different severities of the disease.
3.1 Genetic basis of phenotypic plasticity
It has been found that the mutations with varying phenotypes (MVPs) mostly occur at the less conserved sites with Arg being the usual mutated residue. It is also noted that these mutations commonly occur at the CpG dinucleotides. In comparison, mutations with uniform phenotypes (MUPs) occur in more conserved sites, with cysteine as the most frequently mutated amino acid residue. Intrinsic protein structural changes have been reported with reduced severity in cases of MVPs. No significant structural variations are identified between the two groups. The phenomenon is hypothesised to be a function of multiple factors including modifier genes, epigenetic influences and environmental effects. These factors may act individually or in combination [48].
Tables 4 and 5 depict F8 and F9 mutations, respectively, reported with phenotypic plasticity [49, 50]. A total of 351 mutations are presented here with cases reported from at least two severity classes. The most significant are the 85 cases (32 from F8 and 53 from F9) wherein patients from both severe and mild categories are reported.
| HGVS cDNA | HGVS protein | Mutation type | Mechanism | Exon | Domain | Severe (<1 U/dL) | Moderate (1–5 U/dL) | Mild (>5 U/dL) |
|---|---|---|---|---|---|---|---|---|
| c.1171C>T | p.Arg391Cys | Missense | Substitution | 8 | a1 | X | X | X |
| c.1172G>A | p.Arg391His | Missense | Substitution | 8 | a1 | X | X | X |
| c.1492G>A | p.Gly498Arg | Missense | Substitution | 10 | A2 | X | X | X |
| c.396A>C | p.Glu132Asp | Missense | Substitution | 4 | A1 | X | X | X |
| c.4380delT | p.Asn1460Lysfs*5 | Frameshift | Deletion | 14 | B | X | X | X |
| c.5122C>T | p.Arg1708Cys | Missense | Substitution | 14 | a3 | X | X | X |
| c.5219+3A>G | Splice site change | Substitution | Intron 14 | X | X | X | ||
| c.5399G>A | p.Arg1800His | Missense | Substitution | 16 | A3 | X | X | X |
| c.5663G>T | p.Arg1888Ile | Missense | Substitution | 17 | A3 | X | X | X |
| c.590T>G | p.Val197Gly | Missense | Substitution | 4 | A1 | X | X | X |
| c.6356A>G | p.Gln2119Arg | Missense | Substitution | 22 | C1 | X | X | X |
| c.6371A>G | p.Tyr2124Cys | Missense | Substitution | 22 | C1 | X | X | X |
| c.6506G>A | p.Arg2169His | Missense | Substitution | 23 | C1 | X | X | X |
| c.6545G>A | p.Arg2182His | Missense | Substitution | 23 | C1 | X | X | X |
| c.6683G>A | p.Arg2228Gln | Missense | Substitution | 24 | C2 | X | X | X |
| c.6977G>A | p.Arg2326Gln | Missense | Substitution | 26 | C2 | X | X | X |
| c.902G>A | p.Arg301His | Missense | Substitution | 7 | A1 | X | X | X |
| c.1063C>T | p.Arg355* | Nonsense | Substitution | 8 | A1 | X | X | |
| c.1226A>G | p.Glu409Gly | Missense | Substitution | 8 | A2 | X | X | |
| c.1316G>T | p.Gly439Val | Missense | Substitution | 9 | A2 | X | X | |
| c.143+1567A>G | Splice site change | Substitution | Intron 1 | X | X | |||
| c.1475A>G | p.Tyr492Cys | Missense | Substitution | 10 | A2 | X | X | |
| c.1639T>C | p.Cys547Arg | Missense | Substitution | 11 | A2 | X | X | |
| c.1702G>A | p.Gly568Ser | Missense | Substitution | 11 | A2 | X | X | |
| c.1754T>C | p.Ile585Thr | Missense | Substitution | 12 | A2 | X | X | |
| c.1804C>T | p.Arg602* | Nonsense | Substitution | 12 | A2 | X | X | |
| c.1809C>G | p.Ser603Arg | Missense | Substitution | 12 | A2 | X | X | |
| c.2015_2017del | p.Phe672del | Small structural change (in-frame, <50 bp) | Deletion | 13 | A2 | X | X | |
| c.2048A>G | p.Tyr683Cys | Missense | Substitution | 13 | A2 | X | X | |
| c.206_212del | p.Leu69Glnfs*21 | Frameshift | Deletion | 2 | A1 | X | X | |
| c.2090T>A | p.Val697Asp | Missense | Substitution | 13 | A2 | X | X | |
| c.2114-?_5219+?del | Large structural change (>50 bp) | Deletion | 14 | A3 | X | X | ||
| c.2159G>A | p.Gly720Asp | Missense | Substitution | 14 | A2 | X | X | |
| c.2182delT | p.Ser728Leufs*23 | Frameshift | Deletion | 14 | A2 | X | X | |
| c.2373G>A | p.Trp791* | Nonsense | Substitution | 14 | B | X | X | |
| c.2440C>T | p.Arg814* | Nonsense | Substitution | 14 | B | X | X | |
| c.266G>A | p.Gly89Asp | Missense | Substitution | 3 | A1 | X | X | |
| c.2945dupA | p.Asn982Lysfs*9 | Frameshift | Duplication | 14 | B | X | X | |
| c.296T>A | p.Val99Asp | Missense | Substitution | 3 | A1 | X | X | |
| c.3143G>A | p.Trp1048* | Nonsense | Substitution | 14 | B | X | X | |
| c.3300dupA | p.Glu1101Argfs*17 | Frameshift | Duplication | 14 | B | X | X | |
| c.353A>G | p.His118Arg | Missense | Substitution | 3 | A1 | X | X | |
| c.3637delA | p.Ile1213Phefs*5 | Frameshift | Deletion | 14 | B | X | X | |
| c.3637dupA | p.Ile1213Asnfs*28 | Frameshift | Duplication | 14 | B | X | X | |
| c.3702_3705del | p.His1234Glnfs*2 | Frameshift | Deletion | 14 | B | X | X | |
| c.388G>C | p.Gly130Arg | Missense | Substitution | 3 | A1 | X | X | |
| c.421G>A | p.Glu141Lys | Missense | Substitution | 4 | A1 | X | X | |
| c.4296_4300del | p.His1434Serfs*6 | Frameshift | Deletion | 14 | B | X | X | |
| c.4379dupA | p.Asn1460Lysfs*2 | Frameshift | Duplication | 14 | B | X | X | |
| c.43C>T | p.Arg15* | Nonsense | Substitution | 1 | Signal | X | X | |
| c.4796G>A | p.Trp1599* | Nonsense | Substitution | 14 | B | X | X | |
| c.4825dupA | p.Thr1609Asnfs*4 | Frameshift | Duplication | 14 | B | X | X | |
| c.491G>A | p.Gly164Asp | Missense | Substitution | 4 | A1 | X | X | |
| c.5113C>T | p.Gln1705* | Nonsense | Substitution | 14 | a3 | X | X | |
| c.515G>T | p.Cys172Phe | Missense | Substitution | 4 | A1 | X | X | |
| c.5219G>T | p.Arg1740Met | Missense | Substitution | 14 | A3 | X | X | |
| c.5471dupA | p.Asn1824Lysfs*6 | Frameshift | Duplication | 16 | A3 | X | X | |
| c.5536A>T | p.Lys1846* | Nonsense | Substitution | 16 | A3 | X | X | |
| c.556G>T | p.Asp186Tyr | Missense | Substitution | 4 | A1 | X | X | |
| c.5606G>T | p.Gly1869Val | Missense | Substitution | 17 | A3 | X | X | |
| c.5685delT | p.Phe1895Leufs*50 | Frameshift | Deletion | 17 | A3 | X | X | |
| c.5719A>T | p.Ser1907Cys | Missense | Substitution | 17 | A3 | X | X | |
| c.5878C>T | p.Arg1960* | Nonsense | Substitution | 18 | A3 | X | X | |
| c.5953C>T | p.Arg1985* | Nonsense | Substitution | 18 | A3 | X | X | |
| c.5973_5976del | p.Met1992Hisfs*37 | Frameshift | Deletion | 18 | A3 | X | X | |
| c.5998+1G>A | Splice site change | Substitution | Intron 18 | X | X | |||
| c.5999-?_6429+?dup | Large structural change (>50 bp) | Duplication | 19–22 | X | X | |||
| c.602-?_787+?del | Large structural change (>50 bp) | Deletion | 5–6 | X | X | |||
| c.6046C>T | p.Arg2016Trp | Missense | Substitution | 19 | A3 | X | X | |
| c.6133G>A | p.Gly2045Arg | Missense | Substitution | 20 | C1 | X | X | |
| c.6172G>C | p.Ala2058Pro | Missense | Substitution | 20 | C1 | X | X | |
| c.6274-?_6429+?del | Large structural change (>50 bp) | Deletion | 22 | C1 | X | X | ||
| c.6403C>T | p.Arg2135* | Nonsense | Substitution | 22 | C1 | X | X | |
| c.6429+?_6430-?inv | Large structural change (>50 bp) | Inversion | Intron 22 | X | X | |||
| c.6481C>T | p.Pro2161Ser | Missense | Substitution | 23 | C1 | X | X | |
| c.6485C>T | p.Pro2162Leu | Missense | Substitution | 23 | C1 | X | X | |
| c.6496C>T | p.Arg2166* | Nonsense | Substitution | 23 | C1 | X | X | |
| c.6544C>T | p.Arg2182Cys | Missense | Substitution | 23 | C1 | X | X | |
| c.6593G>T | p.Gly2198Val | Missense | Substitution | 24 | C2 | X | X | |
| c.6682C>G | p.Arg2228Gly | Missense | Substitution | 24 | C2 | X | X | |
| c.6682C>T | p.Arg2228* | Nonsense | Substitution | 24 | C2 | X | X | |
| c.670+5G>A | Splice site change | Substitution | Intron 5 | X | X | |||
| c.6742T>A | p.Trp2248Arg | Missense | Substitution | 25 | C2 | X | X | |
| c.6875_6876del | p.Phe2294Serfs*90 | Frameshift | Deletion | 25 | C2 | X | X | |
| c.6967C>T | p.Arg2323Cys | Missense | Substitution | 26 | C2 | X | X | |
| c.6977G>T | p.Arg2326Leu | Missense | Substitution | 26 | C2 | X | X | |
| c.6994T>C | p.Trp2332Arg | Missense | Substitution | 26 | C2 | X | X | |
| c.764G>C | p.Gly255Ala | Missense | Substitution | 6 | A1 | X | X | |
| c.785C>T | p.Pro262Leu | Missense | Substitution | 6 | A1 | X | X | |
| c.787+3A>G | Splice site change | Substitution | Intron 6 | X | X | |||
| c.822G>C | p.Trp274Cys | Missense | Substitution | 7 | A1 | X | X | |
| c.901C>T | p.Arg301Cys | Missense | Substitution | 7 | A1 | X | X | |
| c.954_955del | p.Leu319Aspfs*18 | Frameshift | Deletion | 7 | A1 | X | X | |
| c.991_992del | p.Ile331Leufs*6 | Frameshift | Deletion | 7 | A1 | X | X | |
| c.1043G>A | p.Cys348Tyr | Missense | Substitution | 8 | A1 | X | X | |
| c.121G>T | p.Gly41Cys | Missense | Substitution | 1 | A1 | X | X | |
| c.1409C>T | p.Pro470Leu | Missense | Substitution | 9 | A2 | X | X | |
| c.1751A>G | p.Gln584Arg | Missense | Substitution | 11 | A2 | X | X | |
| c.1910A>G | p.Asn637Ser | Missense | Substitution | 13 | A2 | X | X | |
| c.3870dupA | p.Gly1291Argfs*29 | Frameshift | Duplication | 14 | B | X | X | |
| c.437A>C | p.Lys146Thr | Missense | Substitution | 4 | A1 | X | X | |
| c.5150A>G | p.Tyr1717Cys | Missense | Substitution | 14 | A3 | X | X | |
| c.5183A>G | p.Tyr1728Cys | Missense | Substitution | 14 | A3 | X | X | |
| c.6273+1G>T | Splice site change | Substitution | Intron 21 | X | X | |||
| c.677G>T | p.Ser226Ile | Missense | Substitution | 6 | A1 | X | X | |
| c.6967C>G | p.Arg2323Gly | Missense | Substitution | 26 | C2 | X | X | |
| c.902G>T | p.Arg301Leu | Missense | Substitution | 7 | A1 | X | X | |
| c.923C>T | p.Ser308Leu | Missense | Substitution | 7 | A1 | X | X | |
| c.1293G>T | p.Leu431Phe | Missense | Substitution | 9 | A2 | X | X | |
| c.1348T>A | p.Tyr450Asn | Missense | Substitution | 9 | A2 | X | X | |
| c.1408C>A | p.Pro470Thr | Missense | Substitution | 9 | A2 | X | X | |
| c.1569G>T | p.= | Synonymous | Substitution | 11 | A2 | X | X | |
| c.1636C>T | p.Arg546Trp | Missense | Substitution | 11 | A2 | X | X | |
| c.1648C>T | p.Arg550Cys | Missense | Substitution | 11 | A2 | X | X | |
| c.1660A>G | p.Ser554Gly | Missense | Substitution | 11 | A2 | X | X | |
| c.1834C>T | p.Arg612Cys | Missense | Substitution | 12 | A2 | X | X | |
| c.2044G>T | p.Val682Phe | Missense | Substitution | 13 | A2 | X | X | |
| c.2149C>T | p.Arg717Trp | Missense | Substitution | 14 | A2 | X | X | |
| c.2167G>A | p.Ala723Thr | Missense | Substitution | 14 | A2 | X | X | |
| c.274G>A | p.Gly92Ser | Missense | Substitution | 3 | A1 | X | X | |
| c.311T>A | p.Val104Asp | Missense | Substitution | 3 | A1 | X | X | |
| c.410C>T | p.Thr137Ile | Missense | Substitution | 4 | A1 | X | X | |
| c.5096A>T | p.Tyr1699Phe | Missense | Substitution | 14 | a3 | X | X | |
| c.5143C>G | p.Arg1715Gly | Missense | Substitution | 14 | A3 | X | X | |
| c.5339C>A | p.Pro1780Gln | Missense | Substitution | 15 | A3 | X | X | |
| c.5393C>T | p.Ala1798Val | Missense | Substitution | 16 | A3 | X | X | |
| c.5398C>G | p.Arg1800Gly | Missense | Substitution | 16 | A3 | X | X | |
| c.541G>A | p.Val181Met | Missense | Substitution | 4 | A1 | X | X | |
| c.5428T>C | p.Ser1810Pro | Missense | Substitution | 16 | A3 | X | X | |
| c.5526G>A | p.Met1842Ile | Missense | Substitution | 16 | A3 | X | X | |
| c.5557G>A | p.Ala1853Thr | Missense | Substitution | 16 | A3 | X | X | |
| c.5618C>T | p.Pro1873Leu | Missense | Substitution | 17 | A3 | X | X | |
| c.5825G>C | p.Gly1942Ala | Missense | Substitution | 18 | A3 | X | X | |
| c.5879G>A | p.Arg1960Gln | Missense | Substitution | 18 | A3 | X | X | |
| c.5921C>T | p.Ser1974Phe | Missense | Substitution | 18 | A3 | X | X | |
| c.5954G>A | p.Arg1985Gln | Missense | Substitution | 18 | A3 | X | X | |
| c.601+1632G>A | Splice site change | Substitution | Intron 4 | X | X | |||
| c.6113A>G | p.Asn2038Ser | Missense | Substitution | 19 | A3 | X | X | |
| c.6119G>A | p.Cys2040Tyr | Missense | Substitution | 20 | C1 | X | X | |
| c.6212G>C | p.Arg2071Thr | Missense | Substitution | 21 | C1 | X | X | |
| c.6278A>G | p.Asp2093Gly | Missense | Substitution | 22 | C1 | X | X | |
| c.6350T>G | p.Ile2117Ser | Missense | Substitution | 22 | C1 | X | X | |
| c.6413C>A | p.Ser2138Tyr | Missense | Substitution | 22 | C1 | X | X | |
| c.6443A>G | p.Asn2148Ser | Missense | Substitution | 23 | C1 | X | X | |
| c.6520C>G | p.His2174Asp | Missense | Substitution | 23 | C1 | X | X | |
| c.6532C>T | p.Arg2178Cys | Missense | Substitution | 23 | C1 | X | X | |
| c.668A>C | p.Glu223Ala | Missense | Substitution | 5 | A1 | X | X | |
| c.670+6T>C | Splice site change | Substitution | Intron 5 | X | X | |||
| c.6744G>T | p.Trp2248Cys | Missense | Substitution | 25 | C2 | X | X | |
| c.67A>G | p.Arg23Gly | Missense | Substitution | 1 | A1 | X | X | |
| c.6915T>G | p.Asn2305Lys | Missense | Substitution | 26 | C2 | X | X | |
| c.6920A>C | p.Asp2307Ala | Missense | Substitution | 26 | C2 | X | X | |
| c.6956C>T | p.Pro2319Leu | Missense | Substitution | 26 | C2 | X | X | |
| c.755C>T | p.Thr252Ile | Missense | Substitution | 6 | A1 | X | X | |
| c.871G>A | p.Glu291Lys | Missense | Substitution | 7 | A1 | X | X |
Table 4.
List of F8 mutations reported with phenotypic plasticity.
| HGVS cDNA name | HGVS protein name | Mutation type | Mechanism | Exon | Domain | Severe (< 1 U/dL) | Moderate (1–5 U/dL) | Mild (>5 U/dL) |
|---|---|---|---|---|---|---|---|---|
| c.87A>G | p.Thr29Thr | Synonymous | Substitution | 1 | PRO | X | X | X |
| c.127C>T | p.Arg43Trp | Missense | Substitution | 2 | PRO | X | X | X |
| c.128G>A | p.Arg43Gln | Missense | Substitution | 2 | PRO | X | X | X |
| c.172G>A | p.Gly58Arg | Missense | Substitution | 2 | GLA | X | X | X |
| c.173G>A | p.Gly58Glu | Missense | Substitution | 2 | GLA | X | X | X |
| c.191G>A | p.Cys64Tyr | Missense | Substitution | 2 | GLA | X | X | X |
| c.259T>G | p.Phe87Val | Missense | Substitution | 3 | GLA | X | X | X |
| c.301C>G | p.Pro101Ala | Missense | Substitution | 4 | EGF1 | X | X | X |
| c.316G>A | p.Gly106Ser | Missense | Substitution | 4 | EGF1 | X | X | X |
| c.412A>C | p.Asn138His | Missense | Substitution | 5 | EGF2 | X | X | X |
| c.415G>A | p.Gly139Ser | Missense | Substitution | 5 | EGF2 | X | X | X |
| c.571C>T | p.Arg191Cys | Missense | Substitution | 6 | Linker | X | X | X |
| c.572G>A | p.Arg191His | Missense | Substitution | 6 | Linker | X | X | X |
| c.720G>T | p.Trp240Cys | Missense | Substitution | 6 | Protease | X | X | X |
| c.755G>A | p.Cys252Tyr | Missense | Substitution | 7 | Protease | X | X | X |
| c.797C>T | p.Ala266Val | Missense | Substitution | 7 | Protease | X | X | X |
| c.835G>A | p.Ala279Thr | Missense | Substitution | 7 | Protease | X | X | X |
| c.838G>C | p.Gly280Arg | Missense | Substitution | 7 | Protease | X | X | X |
| c.881G>A | p.Arg294Gln | Missense | Substitution | 8 | Protease | X | X | X |
| c.914A>G | p.Tyr305Cys | Missense | Substitution | 8 | Protease | X | X | X |
| c.987C>G | p.Ser329Arg | Missense | Substitution | 8 | Protease | X | X | X |
| c.1009G>A | p.Ala337Thr | Missense | Substitution | 8 | Protease | X | X | X |
| c.1025C>T | p.Thr342Met | Missense | Substitution | 8 | Protease | X | X | X |
| c.1135C>T | p.Arg379* | Nonsense | Substitution | 8 | Protease | X | X | X |
| c.1136G>A | p.Arg379Gln | Missense | Substitution | 8 | Protease | X | X | X |
| c.1187G>C | p.Cys396Ser | Missense | Substitution | 8 | Protease | X | X | X |
| c.1235G>A | p.Gly412Glu | Missense | Substitution | 8 | Protease | X | X | X |
| c.1240C>A | p.Pro414Thr | Missense | Substitution | 8 | Protease | X | X | X |
| c.1275A>C | p.Leu425Phe | Missense | Substitution | 8 | Protease | X | X | X |
| c.1304G>A | p.Cys435Tyr | Missense | Substitution | 8 | Protease | X | X | X |
| c.1306G>A | p.Ala436Thr | Missense | Substitution | 8 | Protease | X | X | X |
| c.1328T>C | p.Ile443Thr | Missense | Substitution | 8 | Protease | X | X | X |
| c.*2545A>G | 3′UTR | Substitution | 3′UTR | X | X | X | ||
| c.-17A>G | Promoter | Substitution | 1 | X | X | X | ||
| c.-35G>A | Promoter | Substitution | 5′UTR | X | X | X | ||
| c.-35G>C | Promoter | Substitution | 5′UTR | X | X | X | ||
| c.50T>A | p.Ile17Asn | Missense | Substitution | 1 | Signal peptide | X | X | |
| c.83G>A | p.Cys28Tyr | Missense | Substitution | 1 | Signal peptide | X | X | |
| c.128G>T | p.Arg43Leu | Missense | Substitution | 2 | PRO | X | X | |
| c.138G>T | p.Arg47Ser | Missense | Substitution | 2 | PRO | X | X | |
| c.190T>C | p.Cys64Arg | Missense | Substitution | 2 | GLA | X | X | |
| c.199G>A | p.Glu67Lys | Missense | Substitution | 2 | GLA | X | X | |
| c.219A>C | p.Glu73Asp | Missense | Substitution | 2 | GLA | X | X | |
| c.223C>T | p.Arg75Stop | Nonsense | Substitution | 2 | GLA | X | X | |
| c.226G>A | p.Glu76Lys | Missense | Substitution | 2 | GLA | X | X | |
| c.260T>G | p.Phe87Cys | Missense | Substitution | 3 | GLA | X | X | |
| c.263G>A | p.Trp88* | Nonsense | Substitution | 3 | GLA | X | X | |
| c.291T>G | p.Cys97Trp | Missense | Substitution | 4 | EGF1 | X | X | |
| c.304T>C | p.Cys102Arg | Missense | Substitution | 4 | EGF1 | X | X | |
| c.305G>A | p.Cys102Tyr | Missense | Substitution | 4 | EGF1 | X | X | |
| c.350G>A | p.Cys117Tyr | Missense | Substitution | 4 | EGF1 | X | X | |
| c.383G>A | p.Cys128Tyr | Missense | Substitution | 4 | EGF1 | X | X | |
| c.392delA | p.Asp131fs | Frameshift | Deletion | 5 | EGF2 | X | X | |
| c.414T>A | p.Asn138Lys | Missense | Substitution | 5 | EGF2 | X | X | |
| c.422G>A | p.Cys141Tyr | Missense | Substitution | 5 | EGF2 | X | X | |
| c.423C>A | p.Cys141* | Nonsense | Substitution | 5 | EGF2 | X | X | |
| c.423C>G | p.Cys141Trp | Missense | Substitution | 5 | EGF2 | X | X | |
| c.427C>G | p.Gln143Glu | Missense | Substitution | 5 | EGF2 | X | X | |
| c.434G>A | p.Cys145Tyr | Missense | Substitution | 5 | EGF2 | X | X | |
| c.464G>T | p.Cys155Phe | Missense | Substitution | 5 | EGF2 | X | X | |
| c.470G>A | p.Cys157Tyr | Missense | Substitution | 5 | EGF2 | X | X | |
| c.470G>C | p.Cys157Ser | Missense | Substitution | 5 | EGF2 | X | X | |
| c.479G>T | p.Gly160Val | Missense | Substitution | 5 | EGF2 | X | X | |
| c.482A>G | p.Tyr161Cys | Missense | Substitution | 5 | EGF2 | X | X | |
| c.484C>T | p.Arg162* | Nonsense | Substitution | 5 | EGF2 | X | X | |
| c.509G>A | p.Ser170Tyr | Missense | Substitution | 5 | EGF2 | X | X | |
| c.520G>A | p.Val174Met | Missense | Substitution | 5 | EGF2 | X | X | |
| c.532T>C | p.Cys178Arg | Missense | Substitution | 6 | Linker | X | X | |
| c.535G>A | p.Gly179Arg | Missense | Substitution | 6 | Linker | X | X | |
| c.545_546del | p.Ser182Cysfs*6 | Frameshift | Deletion | 6 | Linker | X | X | |
| c.547delG | p.Val183fs | Frameshift | Deletion | 6 | Linker | X | X | |
| c.676C>T | p.Arg226Trp | Missense | Substitution | 6 | Activation | X | X | |
| c.677G>A | p.Arg226Gln | Missense | Substitution | 6 | Activation | X | X | |
| c.677G>T | p.Arg226Leu | Missense | Substitution | 6 | Activation | X | X | |
| c.688_690del | p.Gly230del | Small structural change (in-frame, <50 bp) | Deletion | 6 | Protease | X | X | |
| c.706G>T | p.Gly236Cys | Missense | Substitution | 6 | Protease | X | X | |
| c.707G>A | p.Gly236Asp | Missense | Substitution | 6 | Protease | X | X | |
| c.711A>G | p.Gln237Gln | Synonymous | Substitution | 6 | Protease | X | X | |
| c.719G>A | p.Trp240* | Nonsense | Substitution | 6 | Protease | X | X | |
| c.719G>T | p.Trp240Leu | Missense | Substitution | 6 | Protease | X | X | |
| c.721C>T | p.Gln241* | Nonsense | Substitution | 6 | Protease | X | X | |
| c.723G>A | p.Gln241Gln | Synonymous | Substitution | 6 | Protease | X | X | |
| c.727_728delinsA | p.Val243fs | Frameshift | Insertion/deletion | 7 | Protease | X | X | |
| c.757G>A | p.Gly253Arg | Missense | Substitution | 7 | Protease | X | X | |
| c.789_790InsT | p.Thr264fs | Frameshift | Insertion | 7 | Protease | X | X | |
| c.799C>T | p.His267Tyr | Missense | Substitution | 7 | Protease | X | X | |
| c.839G>T | p.Gly280Val | Missense | Substitution | 8 | Protease | X | X | |
| c.871G>A | p.Glu291Lys | Missense | Substitution | 8 | Protease | X | X | |
| c.880C>T | p.Arg294* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.881G>T | p.Arg294Leu | Missense | Substitution | 8 | Protease | X | X | |
| c.892C>T | p.Arg298* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.946A>T | p.Ile316Phe | Missense | Substitution | 8 | Protease | X | X | |
| c.990C>A | p.Tyr330* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.1004G>T | p.Cys335Tyr | Missense | Substitution | 8 | Protease | X | X | |
| c.1009G>C | p.Ala337Pro | Missense | Substitution | 8 | Protease | X | X | |
| c.1068G>C | p.Trp356Cys | Missense | Substitution | 8 | Protease | X | X | |
| c.1069G>A | p.Gly357Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1070G>A | p.Gly357Glu | Missense | Substitution | 8 | Protease | X | X | |
| c.1076T>G | p.Val359Gly | Missense | Substitution | 8 | Protease | X | X | |
| c.1097C>A | p.Ala366Asp | Missense | Substitution | 8 | Protease | X | X | |
| c.1108C>T | p.Gln370* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.1113C>A | p.Tyr371* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.1120G>T | p.Val374Glu | Missense | Substitution | 8 | Protease | X | X | |
| c.1135C>G | p.Arg379Gly | Missense | Substitution | 8 | Protease | X | X | |
| c.1144T>C | p.Cys382Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1147C>T | p.Leu383Phe | Missense | Substitution | 8 | Protease | X | X | |
| c.1150C>T | p.Arg384* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.1168A>T | p.Ile390Phe | Missense | Substitution | 8 | Protease | X | X | |
| c.1169T>G | p.Ile390Ser | Missense | Substitution | 8 | Protease | X | X | |
| c.1181T>A | p.Met394Lys | Missense | Substitution | 8 | Protease | X | X | |
| c.1204G>A | p.Gly402Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1217C>G | p.Ser406* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.1217C>T | p.Ser406Leu | Missense | Substitution | 8 | Protease | X | X | |
| c.1219T>C | p.Cys407Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1226G>A | p.Gly409Glu | Missense | Substitution | 8 | Protease | X | X | |
| c.1228G>A | p.Asp410Asn | Missense | Substitution | 8 | Protease | X | X | |
| c.1228G>C | p.Asp410His | Missense | Substitution | 8 | Protease | X | X | |
| c.1232G>A | p.Ser411Asn | Missense | Substitution | 8 | Protease | X | X | |
| c.1237G>A | p.Gly413Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1241C>T | p.Pro414Leu | Missense | Substitution | 8 | Protease | X | X | |
| c.1245T>A | p.His415Gln | Missense | Substitution | 8 | Protease | X | X | |
| c.1256T>A | p.Val419Glu | Missense | Substitution | 8 | Protease | X | X | |
| c.1258G>T | p.Glu420* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.1291T>C | p.Trp431Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1293G>T | p.Trp431Cys | Missense | Substitution | 8 | Protease | X | X | |
| c.1294G>A | p.Gly432Ser | Missense | Substitution | 8 | Protease | X | X | |
| c.1295G>A | p.Gly432Asp | Missense | Substitution | 8 | Protease | X | X | |
| c.1295G>C | p.Gly432Ala | Missense | Substitution | 8 | Protease | X | X | |
| c.1295G>T | p.Gly432Val | Missense | Substitution | 8 | Protease | X | X | |
| c.1297G>A | p.Glu433Lys | Missense | Substitution | 8 | Protease | X | X | |
| c.1298A>C | p.Glu433Ala | Missense | Substitution | 8 | Protease | X | X | |
| c.1307C>T | p.Ala436Val | Missense | Substitution | 8 | Protease | X | X | |
| c.1318A>G | p.Lys440Glu | Missense | Substitution | 8 | Protease | X | X | |
| c.1324G>A | p.Gly442Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1357T>C | p.Trp453Arg | Missense | Substitution | 8 | Protease | X | X | |
| c.1361T>C | p.Ile454Thr | Missense | Substitution | 8 | Protease | X | X | |
| c.*1157A>G | 3′UTR | Substitution | 3′UTR | X | X | |||
| c.252+3_252+6del | Splice site change | Deletion | Intron 2 | X | X | |||
| c.252+6T>C | Splice site change | Substitution | Intron 2 | X | X | |||
| c.253-25A>G | Splice site change | Substitution | Intron 2 | X | X | |||
| c.277+2T>C | Splice site change | Substitution | Intron 3 | X | X | |||
| c.277+5G>A | Splice site change | Substitution | Intron 3 | X | X | |||
| c.392-1G>C | Splice site change | Substitution | Intron 4 | X | X | |||
| c.392-2A>G | Splice site change | Substitution | Intron 4 | X | X | |||
| c.521-3T>G | Splice site change | Substitution | Intron 5 | X | X | |||
| c.-55G>A | Promoter | Substitution | 5′UTR | X | X | |||
| c.723+1G>A | Splice site change | Substitution | Intron 6 | X | X | |||
| c.839-4A>G | Splice site change | Substitution | Intron 7 | X | X | |||
| c.88+1_88+4del | Splice site change | Deletion | Intron 1 | X | X | |||
| c.88+1G>T | Splice site change | Substitution | Intron 1 | X | X | |||
| c.88+5G>C | Splice site change | Substitution | Intron 1 | X | X | |||
| c.88+5G>T | Splice site change | Substitution | Intron 1 | X | X | |||
| c.19A>T | p.Ile7Phe | Missense | Substitution | 1 | Signal peptide | X | X | |
| c.164T>G | p.Phe55Cys | Missense | Substitution | 2 | GLA | X | X | |
| c.339T>A | p.Asn113Lys | Missense | Substitution | 4 | EGF1 | X | X | |
| c.466T>C | p.Ser156Phe | Missense | Substitution | 5 | EGF2 | X | X | |
| c.676C>G | p.Arg226Gly | Missense | Substitution | 6 | Activation | X | X | |
| c.685G>A | p.Gly229Ser | Missense | Substitution | 6 | Protease | X | X | |
| c.907C>T | p.His303Tyr | Missense | Substitution | 8 | Protease | X | X | |
| c.942T>G | p.His314Gln | Missense | Substitution | 8 | Protease | X | X | |
| c.1045G>T | p.Gly349* | Nonsense | Substitution | 8 | Protease | X | X | |
| c.1072A>G | p.Arg358Gly | Missense | Substitution | 8 | Protease | X | X | |
| c.1079T>C | p.Phe360Ser | Missense | Substitution | 8 | Protease | X | X | |
| c.1109A>C | p.Gln370Pro | Missense | Substitution | 8 | Protease | X | X | |
| c.1174A>G | p.Asn392Asp | Missense | Substitution | 8 | Protease | X | X | |
| c.1238G>A | p.Gly413Glu | Missense | Substitution | 8 | Protease | X | X | |
| c.252+5G>A | Splice site change | Substitution | Intron 2 | X | X | |||
| c.839-1G>A | Splice site change | Substitution | Intron 7 | X | X | |||
| c.82T>C | p.Cys28Arg | Missense | Substitution | 1 | Signal peptide | X | X | |
| c.151A>G | p.Lys51Glu | Missense | Substitution | 2 | GLA | X | X | |
| c.163T>A | p.Phe55Ile | Missense | Substitution | 2 | GLA | X | X | |
| c.279T>A | p.Asp93Glu | Missense | Substitution | 4 | EGF1 | X | X | |
| c.335T>C | p.Ile112Thr | Missense | Substitution | 4 | EGF1 | X | X | |
| c.479G>A | p.Gly160Glu | Missense | Substitution | 5 | EGF2 | X | X | |
| c.479G>C | p.Gly160Ala | Missense | Substitution | 5 | EGF2 | X | X | |
| c.484C>A | p.Arg162Arg | Synonymous | Substitution | 5 | EGF2 | X | X | |
| c.572G>C | p.Arg191Pro | Missense | Substitution | 6 | Linker | X | X | |
| c.785T>C | p.Ile262Thr | Missense | Substitution | 7 | Protease | X | X | |
| c.786T>G | p.Ile262Met | Missense | Substitution | 7 | Protease | X | X | |
| c.839G>C | p.Gly280Ala | Missense | Substitution | 8 | Protease | X | X | |
| c.872A>G | p.Glu291Gly | Missense | Substitution | 8 | Protease | X | X | |
| c.950C>T | p.Ala317Val | Missense | Substitution | 8 | Protease | X | X | |
| c.997C>A | p.Pro333Thr | Missense | Substitution | 8 | Protease | X | X | |
| c.1067G>T | p.Trp356Leu | Missense | Substitution | 8 | Protease | X | X | |
| c.1097C>T | p.Ala366Val | Missense | Substitution | 8 | Protease | X | X | |
| c.1127T>C | p.Leu376Pro | Missense | Substitution | 8 | Protease | X | X | |
| c.1180A>G | p.Met394Val | Missense | Substitution | 8 | Protease | X | X | |
| c.1187G>T | p.Cys396Phe | Missense | Substitution | 8 | Protease | X | X | |
| c.1193G>C | p.Gly398Ala | Missense | Substitution | 8 | Protease | X | X | |
| c.1348T>C | p.Tyr450His | Missense | Substitution | 8 | Protease | X | X | |
| c.-48G>C | Promoter | Substitution | 5′UTR | X | X | |||
| c.-49T>A | Promoter | Substitution | 5′UTR | X | X | |||
| c.520+13A>G | Splice site change | Substitution | Intron 5 | X | X | |||
| c.88+5G>A | Splice site change | Substitution | Intron 1 | X | X |
Table 5.
List of F9 mutations reported with phenotypic plasticity.
Taking into account the significant amount of phenotypic plasticity in haemophilia, researchers have proposed to recognise the disease phenotype, in terms of coagulation activity, a continuous variable and abandoning of the classical categorical classification [51]. With the evolving concepts of personalised medicine, this may prove realistic… and the future.
References
- 1.
Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Seminars in Thrombosis and Hemostasis. 2008; 34 (1):128-141 - 2.
Wojczynski MK, Tiwari HK. Definition of phenotype. Advances in Genetics. 2008; 60 :75-105 - 3.
Schulze TG, McMahon FJ. Defining the phenotype in human genetic studies: Forward genetics and reverse phenotyping. Human Heredity. 2004; 58 (3–4):131-138 - 4.
Winawer MR. Phenotype definition in epilepsy. Epilepsy & Behavior: E&B. 2006; 8 (3):462-476 - 5.
Gottesman II, Gould TD. The endophenotype concept in psychiatry: Etymology and strategic intentions. The American Journal of Psychiatry. 2003; 160 (4):636-645 - 6.
Schramm W. The history of haemophilia—A short review. Thrombosis Research. 2014; 134 (Supp. 1):S4-S9 - 7.
Ingram GI. The history of haemophilia. Journal of Clinical Pathology. 1976; 29 (6):469-479 - 8.
Franchini M, Mannucci PM. Past, present and future of hemophilia: A narrative review. Orphanet Journal of Rare Diseases. 2012; 7 :24 - 9.
White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis. 2001; 85 (3):560 - 10.
Konkle BA, Josephson NC, Nakaya Fletcher S. Hemophilia B. In: GeneReviews®. Seattle, WA: University of Washington, Seattle. 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1495/ - 11.
Konkle BA, Huston H, Nakaya Fletcher S. Hemophilia A. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA): University of Washington, Seattle; 1993. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved - 12.
van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. Journal of Thrombosis and Haemostasis. 2007; 5 (Supp. 1):151-156 - 13.
Khan MTM, Naz A, Ahmed J, Shamsi T, Ahmed S, Ahmed N, et al. Mutation spectrum and genotype-phenotype analyses in a Pakistani cohort with hemophilia B. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2018; 24 (5):741-748 - 14.
Zhao H, Yang Y, Lu Y, Mort M, Cooper DN, Zuo Z, et al. Quantitative mapping of genetic similarity in human heritable diseases by shared mutations. Human Mutation. 2018; 39 (2):292-301 - 15.
Graw J, Brackmann HH, Oldenburg J, Schramm W, Schwaab R, editors. Genotype-phenotype correlation in hemophilia A. In: 30th Hemophilia Symposium Hamburg 1999; Berlin/Heidelberg: Springer; 2001 - 16.
Zlotogora J. Penetrance and expressivity in the molecular age. Genetics in Medicine: Official Journal of the American College of Medical Genetics. 2003; 5 (5):347-352 - 17.
Pavlova A, Oldenburg J. Defining severity of hemophilia: More than factor levels. Seminars in Thrombosis and Hemostasis. 2013; 39 (7):702-710 - 18.
Baye TM, Abebe T, Wilke RA. Genotype-environment interactions and their translational implications. Personalized Medicine. 2011; 8 (1):59-70 - 19.
Chanda P, Sucheston L, Liu S, Zhang A, Ramanathan M. Information-theoretic gene-gene and gene-environment interaction analysis of quantitative traits. BMC Genomics. 2009; 10 :509 - 20.
Guo SW. Gene-environment interaction and the mapping of complex traits: Some statistical models and their implications. Human Heredity. 2000; 50 (5):286-303 - 21.
Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. Journal of Thrombosis and Haemostasis. 2013; 11 (7):1329-1340 - 22.
Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, et al. Bleeding in carriers of hemophilia. Blood. 2006; 108 (1):52-56 - 23.
Paroskie A, Gailani D, DeBaun MR, Sidonio RF Jr. A cross-sectional study of bleeding phenotype in haemophilia A carriers. British Journal of Haematology. 2015; 170 (2):223-228 - 24.
Khan MTM, Naz A, Ahmed J, Shamsi TS, Taj AS. Diagnosis and phenotypic assessment of Pakistani haemophilia B carriers. Pakistan Journal of Medical Sciences. 2017; 33 (3):738-742 - 25.
Picketts DJ, Lillicrap DP, Mueller CR. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Nature Genetics. 1993; 3 (2):175-179 - 26.
Giannelli F, Green PM, Sommer SS, Poon MC, Ludwig M, Schwaab R, et al. Haemophilia B (sixth edition): A database of point mutations and short additions and deletions. Nucleic Acids Research. 1996; 24 (1):103-118 - 27.
Crossley M, Winship PR, Austen DE, Rizza CR, Brownlee GG. A less severe form of haemophilia B Leyden. Nucleic Acids Research. 1990; 18 (15):4633 - 28.
Belvini D, Salviato R, Radossi P, Pierobon F, Mori P, Castaldo G, et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica. 2005; 90 (5):635-642 - 29.
Ketterling RP, Liu JZ, Liao D, Kasper CK, Ambriz R, Paredes R, et al. Two novel factor IX promoter mutations: Incremental progress towards ‘saturation in vivo mutagenesis’ of a human promoter region. Human Molecular Genetics. 1995; 4 (4):769-770 - 30.
Reijnen MJ, Peerlinck K, Maasdam D, Bertina RM, Reitsma PH. Hemophilia B Leyden: Substitution of thymine for guanine at position −21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood. 1993; 82 (1):151-158 - 31.
Reitsma PH, Bertina RM, Ploos van Amstel JK, Riemens A, Briet E. The putative factor IX gene promoter in hemophilia B Leyden. Blood. 1988; 72 (3):1074-1076 - 32.
Ghanem N, Costes B, Martin J, Vidaud M, Rothschild C, Foyer-Gazengel C, et al. Twenty-four novel hemophilia B mutations revealed by rapid scanning of the whole factor IX gene in a French population sample. European Journal of Human Genetics. 1993; 1 (2):144-155 - 33.
Hirosawa S, Fahner JB, Salier JP, Wu CT, Lovrien EW, Kurachi K. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: Factor IX Leyden. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87 (12):4421-4425 - 34.
Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, et al. The human gene mutation database: 2008 update. Genome Medicine. 2009; 1 (1):13 - 35.
Picketts DJ, D’Souza C, Bridge PJ, Lillicrap D. An A to T transversion at position −5 of the factor IX promoter results in hemophilia B. Genomics. 1992; 12 (1):161-163 - 36.
Royle G, Van de Water NS, Berry E, Ockelford PA, Browett PJ. Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region. British Journal of Haematology. 1991; 77 (2):191-194 - 37.
Reitsma PH, Mandalaki T, Kasper CK, Bertina RM, Briet E. Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype). Blood. 1989; 73 (3):743-746 - 38.
Bowen DJ. Haemophilia A and haemophilia B: Molecular insights. Molecular Pathology. 2002; 55 (1):1-18 - 39.
Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: An androgen-responsive element in the factor IX promoter. Science. 1992; 257 (5068):377-379 - 40.
Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). The New England Journal of Medicine. 2009; 361 (17):1671-1675 - 41.
Chang J, Jin J, Lollar P, Bode W, Brandstetter H, Hamaguchi N, et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. The Journal of Biological Chemistry. 1998; 273 (20):12089-12094 - 42.
van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000; 95 (12):3678-3682 - 43.
van Minkelen R, de Visser MC, van Hylckama Vlieg A, Vos HL, Bertina RM. Sequence variants and haplotypes of the factor IX gene and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis. 2008; 6 (9):1610-1613 - 44.
Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, et al. Gene variants associated with deep vein thrombosis. JAMA. 2008; 299 (11):1306-1314 - 45.
Bezemer ID, Arellano AR, Tong CH, Rowland CM, Ireland HA, Bauer KA, et al. F9 Malmo, factor IX and deep vein thrombosis. Haematologica. 2009; 94 (5):693-699 - 46.
Stanley TB, Jin DY, Lin PJ, Stafford DW. The propeptides of the vitamin K-dependent proteins possess different affinities for the vitamin K-dependent carboxylase. The Journal of Biological Chemistry. 1999; 274 (24):16940-16944 - 47.
Fusco G, Minelli A. Phenotypic plasticity in development and evolution: Facts and concepts. Philosophical Transactions of the Royal Society, B: Biological Sciences. 2010; 365 (1540):547-556 - 48.
Chavali S, Sharma A, Tabassum R, Bharadwaj D. Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX. Proteins. 2008; 73 (1):63-71 - 49.
Li T, Miller CH, Payne AB, Craig Hooper W. The CDC hemophilia B mutation project mutation list: A new online resource. Molecular Genetics & Genomic Medicine. 2013; 1 (4):238-245 - 50.
Payne AB, Miller CH, Kelly FM, Michael Soucie J, Craig Hooper W. The CDC hemophilia A mutation project (CHAMP) mutation list: A new online resource. Human Mutation. 2013; 34 (2):E2382-E2391 - 51.
Chavali S, Ghosh S, Bharadwaj D. Hemophilia B is a quasi-quantitative condition with certain mutations showing phenotypic plasticity. Genomics. 2009; 94 (6):433-437